-
公开(公告)号：EP3335043A1
公开(公告)日：2018-06-20
申请号：EP16836011.3
申请日：2016-08-12
发明人： MORAITIS, Andreas G.
IPC分类号： G01N33/50 , A61K31/575 , C07D217/08
CPC分类号： G01N33/74 , A61K31/4745 , A61K31/567 , A61K31/573 , G01N2333/695 , G01N2800/048
摘要： This invention provides for an improved method for differentially diagnosing ACTH-dependent Cushing's syndrome. Current practice for differentially diagnosing ectopic ACTH syndrome and Cushing's Disease measures relative ACTH concentrations from the inferior petrosal venous sinus compared to fluid obtained from a periphery venous sample. This is performed before and after administration of exogenous corticotropin releasing factor, or after administration of metyrapone. This invention uses glucocorticoid receptor antagonists to induce release of endogenous CRH which stimulates ACTH to increase in patients with ectopic ACTH syndrome but not in those with Cushing's Disease.
-
2.发明公开METHOD FOR PREDICTING A TREATMENT RESPONSE TO A V1B RECEPTOR ANTAGONIST IN A PATIENT WITH DEPRESSIVE SYMPTOMS AND/OR ANXIETY SYMPTOMS 审中-公开用于预测对具有抑郁症状和/或焦虑症状的患者中的V1B受体拮抗剂的治疗反应的方法
公开(公告)号：EP3276010A1
公开(公告)日：2018-01-31
申请号：EP17168747.8
申请日：2013-06-17
申请人： B.R.A.H.M.S GmbH
发明人： Struck, Joachim , Holsboer, Florian
CPC分类号： A61K31/405 , A61K31/404 , A61K31/573 , A61K45/06 , C07K14/723 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , G01N33/57407 , G01N33/57434 , G01N33/68 , G01N33/6893 , G01N2800/048 , G01N2800/301 , G01N2800/304 , G01N2800/52 , A61K2300/00
摘要： The invention relates to a method for predicting a treatment response to a V 1B receptor antagonist in a patient with depressive symptoms and/or anxiety symptoms, wherein the copeptin concentration in a blood sample of said patient is determined and/or the AVP concentration in a sample of cerebrospinal fluid of said patient is determined and wherein an elevated copeptin and/or an elevated AVP concentration compared to copeptin and/or AVP concentrations in healthy individuals is indicative for a patient responding to a treatment with a V 1B receptor antagonist.
摘要翻译： 本发明涉及用于预测患有抑郁症状和/或焦虑症状的患者中对V1B受体拮抗剂的治疗反应的方法，其中确定所述患者的血液样品中的和肽素浓度和/或样品中的AVP浓度 确定了所述患者的脑脊髓液，并且其中与健康个体中和肽素和/或AVP浓度相比升高的和肽素和/或升高的AVP浓度指示患者对用V1B受体拮抗剂进行的治疗有反应。
-
3.发明公开V1B RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF PATIENTS HAVING AN ELEVATED AVP LEVEL AND/OR AN ELEVATED COPEPTIN LEVEL 审中-公开V1B受体拮抗剂患者的具有增加AVP镜子和/或增加肽素明镜的治疗
公开(公告)号：EP2861253A1
公开(公告)日：2015-04-22
申请号：EP13729363.5
申请日：2013-06-17
发明人： HOLSBOER, Florian
IPC分类号： A61K45/00 , A61K31/404 , C07K14/575 , G01N33/68
CPC分类号： A61K31/405 , A61K31/404 , A61K31/573 , A61K45/00 , A61K45/06 , C07K14/723 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , G01N33/57407 , G01N33/57434 , G01N33/68 , G01N33/6893 , G01N2800/048 , G01N2800/301 , G01N2800/304 , G01N2800/52 , A61K2300/00
摘要： The invention relates to a method for predicting a treatment response to a V 1B receptor antagonist in a patient with depressive symptoms and/or anxiety symptoms, wherein the copeptin concentration in a blood sample of said patient is determined and/or the AVP concentration in a sample of cerebrospinal fluid of said patient is determined and wherein an elevated copeptin and/or an elevated AVP concentration compared to copeptin and/or AVP concentrations in healthy individuals is indicative for a patient responding to a treatment with a V 1B receptor antagonist.
-
4.发明公开METHODS OF DIAGNOSIS AND TREATMENT OF EQUINE LAMINITIS AND CUSHING' S SYNDROME 审中-公开方法进行诊断和蹄叶炎治疗和库欣综合征马
公开(公告)号：EP2013629A1
公开(公告)日：2009-01-14
申请号：EP07732655.1
申请日：2007-05-02
CPC分类号： G01N33/74 , A23K20/111 , A23K50/20 , A61K31/13 , G01N33/9406 , G01N33/9413 , G01N33/942 , G01N2800/048
摘要： The invention provides a method for diagnosing a disorder or disease associated with an imbalance of monoamines in a subject, or of diagnosing susceptibility of the subject to the same, wherein the method comprising (a) providing a sample from a subject to be tested, (b) measuring the levels of dopamine, melatonin and/or serotonin in the sample; and (c) comparing the levels measured in step (b) with levels of dopamine, melatonin and/or serotonin associated with a reference population of subjects, wherein a difference in one or more of the levels measured in step (b) with the levels of dopamine, melatonin and serotonin associated with the reference population of subjects is indicative of a positive diagnosis. The invention further provides a method of prevention or treatment of a disorder or disease associated with an imbalance of monoamines, and kits for the same.
-
-
-
搜索结果
4 条记录 (耗时 0.013 秒)
